Trial · NCT01652573
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Area Under the Curve for FGF23 | Time 0 | FGF23 will be measured 0 to 24 hours post dose during a 24 hour admission and AUC calculated. |
| Primary | Area Under the Curve for FGF23 | 3 months | FGF23 will be measured 0 to 24 hours post dose during a 24 hour admission at 3 months and AUC calculated and compared to baseline. |
| Secondary | Area Under the Curve for TmP/GFR | Time 0 | Serum phosphate will be measured 0 to 24 hours postdose during a 24 hr admission, AUC calculated, and fasting Tmp/GFR calculated. |
| Secondary | Area Under the Curve for 1,25(OH)2vitamin D | Time 0 | Serum 1,25(OH)2vitamin D will be measured 0 to 24 hours post dose during a 24 hr admission and AUC calculated. |
| Secondary | Number of Patients With Nasal Congestion at Baseline | Time 0 | This symptom will be assessed at baseline |
| Secondary | Area Under the Curve for TmP/GFR | Time 3 months | TmP/GFR will be measured 0 to 24 hours postdose during a 24 hr admission at 3 months and AUC calculated and compared to baseline. |
| Secondary | Area Under the Curve for 1,25(OH)2vitamin D | Time 3 months | Serum 1,25(OH)2vitamin D will be measured 0 to 24 hours post dose during a 24 hr admission and AUC calculated and results will be compared to baseline values. |
| Secondary | Number of Participants With Nasal Congestion at 1 Month | Time 1 month | This symptom will be assessed. |
| Secondary | Number of Participants With Nasal Congestion at 2 Months | Time 2 months | This symptom will be assessed. |
| Secondary | Number of Participants With Nasal Congestion at 3 Months | Time 3 months | This symptom will be assessed. |
| Secondary | Number of Participants With Nasal Ulcerations at Baseline | Time 0 | This symptom will be assessed at baseline |
| Secondary | Number of Participants With Allergic Reactions at Baseline | Time 0 | This symptom will be assessed at baseline |
| Secondary | Number of Participants With Nasal Ulceration at 1 Month | Time 1 month | This symptom will be assessed. |
| Secondary | Number of Participants With Allergic Reactions at 1 Month | Time 1 month | This symptom will be assessed. |
| Secondary | Number of Participants With Nasal Ulceration at 2 Months | Time 2 months | This symptom will be assessed. |
| Secondary | Number of Participants With Allergic Reactions at 2 Months | Time 2 months | This symptom will be assessed. |
| Secondary | Number of Participants With Nasal Ulcerations at 3 Months | Time 3 months | This symptom will be assessed. |
| Secondary | Number of Participants With Allergic Reactions at 3 Months | Time 3 months | This symptom will be assessed. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01652573/registered